Canopy Growth Corporation (CGC)
USD 2.83
(-7.21%)
USD 2.83
(-7.21%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 80.88 Million CAD | 177.67% |
| 2022 | -104.14 Million USD | 46.06% |
| 2021 | -193.05 Million CAD | -388.31% |
| 2020 | 66.96 Million CAD | 311.34% |
| 2019 | -31.68 Million CAD | -135.63% |
| 2018 | 88.93 Million CAD | 19.86% |
| 2017 | 74.19 Million CAD | 97.15% |
| 2016 | 37.63 Million CAD | 486.9% |
| 2015 | 6.41 Million CAD | 1447.49% |
| 2014 | 414.34 Thousand CAD | 0.0% |
| 2013 | - CAD | -100.0% |
| 2012 | 4144.00 CAD | 0.0% |
| 2011 | - CAD | -100.0% |
| 2010 | 4488.00 CAD | 717.49% |
| 2009 | 549.00 CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 12.41 Million USD | 178.59% |
| 2023 Q3 | 28.22 Million USD | 20.49% |
| 2023 FY | 80.88 Million USD | 177.67% |
| 2023 Q1 | 5.93 Million USD | 106.56% |
| 2023 Q2 | 23.42 Million USD | 294.58% |
| 2023 Q4 | 6.1 Million USD | -78.38% |
| 2022 Q3 | -2.44 Million CAD | -163.88% |
| 2022 FY | -104.14 Million USD | 46.06% |
| 2022 Q1 | -1.39 Million CAD | 99.13% |
| 2022 Q4 | -90.5 Million USD | -3607.66% |
| 2022 Q2 | 3.82 Million CAD | 374.5% |
| 2021 Q1 | 27.23 Million CAD | 177.94% |
| 2021 Q2 | -71.14 Million CAD | -361.18% |
| 2021 Q3 | 10.09 Million CAD | 114.18% |
| 2021 Q4 | -159.24 Million CAD | -1678.22% |
| 2021 FY | -193.05 Million CAD | -388.31% |
| 2020 Q2 | 26.08 Million CAD | 301.54% |
| 2020 Q3 | 24.58 Million CAD | -5.73% |
| 2020 Q4 | 9.8 Million CAD | -60.14% |
| 2020 Q1 | 6.49 Million CAD | 103.16% |
| 2020 FY | 66.96 Million CAD | 311.34% |
| 2019 Q2 | 3.52 Million CAD | -80.74% |
| 2019 Q1 | 18.29 Million CAD | -73.29% |
| 2019 Q4 | -205.62 Million CAD | -441.41% |
| 2019 FY | -31.68 Million CAD | -135.63% |
| 2019 Q3 | 60.22 Million CAD | 1609.59% |
| 2018 FY | 88.93 Million CAD | 19.86% |
| 2018 Q1 | 7.46 Million CAD | 4.0% |
| 2018 Q2 | -33.98 Million CAD | -555.31% |
| 2018 Q3 | 12.45 Million CAD | 136.64% |
| 2018 Q4 | 68.47 Million CAD | 449.93% |
| 2017 FY | 74.19 Million CAD | 97.15% |
| 2017 Q4 | 7.17 Million CAD | -61.35% |
| 2017 Q3 | 18.57 Million CAD | 121.18% |
| 2017 Q2 | 8.39 Million CAD | -38.1% |
| 2017 Q1 | 13.56 Million CAD | 857.23% |
| 2016 FY | 37.63 Million CAD | 486.9% |
| 2016 Q4 | 1.41 Million CAD | -44.67% |
| 2016 Q2 | 1.16 Million CAD | -66.07% |
| 2016 Q1 | 3.44 Million CAD | 28.16% |
| 2016 Q3 | 2.56 Million CAD | 119.08% |
| 2015 Q4 | 2.68 Million CAD | -2.47% |
| 2015 FY | 6.41 Million CAD | 1447.49% |
| 2015 Q3 | 2.75 Million CAD | 161.03% |
| 2015 Q2 | -4.51 Million CAD | -569.17% |
| 2015 Q1 | -674.84 Thousand CAD | -177.48% |
| 2014 Q1 | 109.77 Thousand CAD | 177.64% |
| 2014 FY | 414.34 Thousand CAD | 0.0% |
| 2014 Q4 | -243.2 Thousand CAD | -205.47% |
| 2014 Q3 | 230.59 Thousand CAD | 209.62% |
| 2014 Q2 | 74.47 Thousand CAD | -32.16% |
| 2013 Q2 | 997.00 CAD | 1977.08% |
| 2013 Q3 | 48.00 CAD | -95.19% |
| 2013 FY | - CAD | -100.0% |
| 2013 Q4 | -141.39 Thousand CAD | -294668.75% |
| 2013 Q1 | 48.00 CAD | -95.03% |
| 2012 Q4 | 965.00 CAD | -3.69% |
| 2012 Q1 | 1002.00 CAD | 0.0% |
| 2012 Q2 | - CAD | -100.0% |
| 2012 Q3 | 1002.00 CAD | 0.0% |
| 2012 FY | 4144.00 CAD | 0.0% |
| 2011 Q4 | - CAD | -100.0% |
| 2011 Q3 | 1185.00 CAD | -4.97% |
| 2011 Q1 | 1247.00 CAD | 3.31% |
| 2011 FY | - CAD | -100.0% |
| 2011 Q2 | 1247.00 CAD | 0.0% |
| 2010 Q4 | 1207.00 CAD | -18.72% |
| 2010 Q3 | 1485.00 CAD | 0.0% |
| 2010 Q2 | - CAD | -100.0% |
| 2010 Q1 | 549.00 CAD | 0.0% |
| 2010 FY | 4488.00 CAD | 717.49% |
| 2009 FY | 549.00 CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Theratechnologies Inc. | 62.12 Million USD | -30.184% |
| Harrow Health, Inc. | 90.55 Million USD | 10.68% |
| Dynavax Technologies Corporation | 182.11 Million USD | 55.588% |
| Biofrontera Inc. | 16.62 Million USD | -386.45% |
| Cronos Group Inc. | 6.99 Million USD | -1056.962% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -1604.573% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 81.666% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 26793.729% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -2548.246% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -141.54% |
| Radius Health, Inc. | 307.71 Million USD | 73.715% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -702.57% |
| DURECT Corporation | 6.83 Million USD | -1084.043% |
| ProPhase Labs, Inc. | 16.23 Million USD | -398.073% |
| Safety Shot Inc | -74.45 Thousand USD | 108729.142% |
| Phibro Animal Health Corporation | 312.48 Million USD | 74.117% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -14500.403% |
| Alvotech | -69.42 Million USD | 216.508% |
| Assertio Holdings, Inc. | 125.04 Million USD | 35.32% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 84.557% |
| Rockwell Medical, Inc. | 8.7 Million USD | -829.251% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -869.905% |
| Procaps Group S.A. | 239.56 Million USD | 66.239% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 81.218% |
| SCYNEXIS, Inc. | 124.51 Million USD | 35.043% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -48.174% |
| Viatris Inc. | 6.43 Billion USD | 98.744% |
| OptiNose, Inc. | 62.35 Million USD | -29.714% |
| SIGA Technologies, Inc. | 122.09 Million USD | 33.753% |
| Tilray Brands, Inc. | 223.35 Million USD | 63.787% |
| PetIQ, Inc. | 252.74 Million USD | 67.998% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -869.905% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 95.622% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -1399.337% |
| Alimera Sciences, Inc. | 61.17 Million USD | -32.225% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 75.202% |
| Silver Spike Investment Corp. | 8.1 Million USD | -898.223% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 1187620.188% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 73.891% |
| Journey Medical Corporation | 52.52 Million USD | -53.999% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -1829.82% |
| Alpha Teknova, Inc. | 10.29 Million USD | -685.567% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -1133.71% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -93.266% |
| PainReform Ltd. | -15 Thousand USD | 539313.333% |
| Cosmos Health Inc. | 4.34 Million USD | -1759.541% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -198.27% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -6112.135% |
| Embecta Corp. | 749.9 Million USD | 89.214% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 10948.082% |
| Talphera, Inc. | -4.89 Million USD | 1752.339% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 83.504% |
| Incannex Healthcare Limited | 12 Thousand USD | -673916.667% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 3455.855% |
| Shineco, Inc. | 882.16 Thousand USD | -9068.548% |
| Procaps Group, S.A. | 239.56 Million USD | 66.239% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 73.508% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -171.854% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 88.601% |
| Alvotech | -69.42 Million USD | 216.508% |
| Hempacco Co., Inc. | -1.21 Million USD | 6752.394% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 63.513% |
| Bright Green Corporation | -237.01 Thousand USD | 34225.122% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -10.696% |
| Kamada Ltd. | 52.59 Million USD | -53.789% |
| Indivior PLC | 907 Million USD | 91.082% |
| Evoke Pharma, Inc. | 4.97 Million USD | -1524.544% |
| Flora Growth Corp. | 17.73 Million USD | -355.982% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 3455.855% |
| Evolus, Inc. | 140.52 Million USD | 42.443% |
| HUTCHMED (China) Limited | 453.55 Million USD | 82.167% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 76.486% |
| Akanda Corp. | 111.44 Thousand USD | -72473.105% |